ToddMCooperDO

Pediatric Hematology & Oncology • Seattle, WA

Physician

Join to view full profile

Dr. Cooper is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cooper's full profile

Already have an account?

Office
4800 Sand Point Way NE
Seattle, WA 98105
Phone+1 206-987-2106

Fax+1 206-987-3946

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2001 - 2004
USA HealthResidency, Pediatrics, 1998 - 2001
Nova Southeastern University College of Osteopathic MedicineClass of 1998

Certifications & Licensure

WA State License 2014 - 2025
AK State License 2021 - 2022
GA State License 2008 - 2016
AL State License 1999 - 2008
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Start of enrollment: 2001 Feb 01
Unknown status
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2009 Sep 21
Completed
Phase 1, Phase 2
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Sep 01
Terminated
Not Applicable
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL Start of enrollment: 2011 Nov 01
Completed
Phase 1
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Start of enrollment: 2020 Jul 21
Active, not recruiting
Phase 3
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group.
Andrew J Menssen, Chad A Hudson, Todd Alonzo, Robert Gerbing, Laura Pardo
Haematologica. 2024-10-01
34 citations
Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Kelly D. Getz, Lillian Sung, Todd A. Alonzo, Kasey J. Leger, Robert B. Gerbing
Journal of Clinical Oncology. 2020-04-28
24 citations
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report ...
Todd M. Cooper, Michael J. Absalon, Todd A. Alonzo, Robert B. Gerbing, Kasey J. Leger
Journal of Clinical Oncology. 2020-05-13

Lectures

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Navigating Treatment Options and Communication in Relapsed Pediatric AMLJune 1st, 2024
BBI Funds ‘Entirely Novel Approach’ to Studying Pediatric LeukemiaFebruary 28th, 2022
Viewing: CBDC Quality Program Charter, 13173October 11th, 2021
Join now to see all

ToddMCooperDO

Dr. Cooper is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.